Core Viewpoint - The company has approved a share repurchase plan, aiming to enhance shareholder value and investor confidence while maintaining operational stability and compliance with regulations [1][6]. Group 1: Share Repurchase Plan - The company will repurchase A-shares through centralized bidding in the secondary market, with a total fund amount not less than RMB 600 million and not exceeding RMB 1.2 billion, at a maximum price of RMB 157 per share [1]. - The repurchase price cap was adjusted to RMB 155.27 per share effective from June 28, 2024, due to dividend distributions and other corporate actions [2]. - As of the announcement date, the company has completed the repurchase of 12,300,701 shares, accounting for 3.6161% of the total A-share capital, with a total expenditure of approximately RMB 999.64 million [4]. Group 2: Implementation Details - The repurchase was conducted from March 7, 2024, to February 18, 2025, with the highest transaction price at RMB 102.00 and the lowest at RMB 71.65 per share [4]. - The company has adhered to the relevant regulations during the repurchase process, ensuring compliance with the Shenzhen Stock Exchange's guidelines [9][10]. Group 3: Impact and Future Plans - The share repurchase is expected to establish a long-term incentive mechanism, protect shareholder rights, and enhance investor confidence without significantly impacting the company's operations or financial health [6]. - The repurchased shares will be stored in a dedicated account and will not have voting rights or profit distribution rights during the holding period, with plans for future use in equity incentives or capital reduction [11].
凯莱英医药集团(天津)股份有限公司 关于股份回购完成暨股份变动的公告